title: [Survey of continuous renal replacement therapy application status].
abstract: Objective:To investigate the condition of implementation of continuous renal replacement therapy (CRRT) in quality control center of critical care medicine.Methods:Questionnaire mails were issued to all of the quality control respondents to survey the application of CRRT in June 2015 from Jiangsu quality control center of critical care medicine.Results:Among the 69 quality control respondents, 62 were equipped with CRRT devices, and in 58 of which patients were treated with CRRT. There were 195 doctors and 253 nurses in 62 quality control respondents attended CRRT training at or above the provincial level; the proportions of hospitals in southern, central and northern regions of Jiangsu were 63%, 79% and 86% respectively with trained doctors (more than 2), and 34%, 38% and 43% respectively with trained nurses (more than 3). The preferred material for CRRT filter were AN69 and acrylic, accounting for 48% and 45% respectively. The average life span was less than 12 h for 21% filters, 12-24 h for 34% filters, and more than 72 h for only 2% filters. Manual displacement liquids were currently mainly used in our province, accounting for 75%. Heparin is the most frequently used anticoagulants, accounting for 48%. Citrate and low molecular weight heparin used for anticoagulation accounted for 31% and 21% respectively. Bleeding was the most common clinical complication (43%) in patients with CRRT, followed by low temperature (22%). The average hospitalization expenses for patients with CRRT amounted to 69 643 yuan RMB per person, in which the cost for CRRT accounted for 19 525 yuan RMB per person.Conclusion:The application of CRRT varies in filter materials, anticoagulants, replacement frequencies and dilution mode. Bleeding is the most common clinical complication in patients with CRRT. Besides, the proportion of trained doctors and nurses at the provincial level is still very low. It will be improved with intensive training and reasonable implementation for us to prolong the lifespan of the filters and reduce the cost for patients with CRRT.
authors.affiliation: Department of Critical Care Medicine, Zhongda Hospital and School of Clinical Medicine, Southeast University, Nanjing 210009, China.
authors.forename: C S
authors.initials: CS
authors.lastname: Yang
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.forename: L W
authors.initials: LW
authors.lastname: Huang
authors.forename: X W
authors.initials: XW
authors.lastname: Zhang
authors.forename: S Q
authors.initials: SQ
authors.lastname: Liu
authors.forename: H B
authors.initials: HB
authors.lastname: Qiu
mesh_terms: D000925:Anticoagulants; D001777:Blood Coagulation; D002951:Citrates; D003422:Critical Care; D005440:Fluid Therapy; D006470:Hemorrhage; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006801:Humans; D017582:Renal Replacement Therapy; D011795:Surveys and Questionnaires
chemical_list: D000925:Anticoagulants; D002951:Citrates; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin